Shattuck Labs, Inc. Deferred Tax Assets, Capital Loss Carryforwards
Shattuck Labs, Inc. (STTK) had Deferred Tax Assets, Capital Loss Carryforwards of $556.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Capital Loss Carryforwards $556.00K.
- 2024-12-31: Deferred Tax Assets, Capital Loss Carryforwards $576.00K.
- 2023-12-31: Deferred Tax Assets, Capital Loss Carryforwards $583.00K.
- 2022-12-31: Deferred Tax Assets, Capital Loss Carryforwards $583.00K.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2025-12-31 | $556.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $576.00K 10-K · filed 2026-03-05 |
| 2023-12-31 | $583.00K 10-K · filed 2025-03-27 |
| 2022-12-31 | $583.00K 10-K · filed 2024-02-29 |
| 2021-12-31 | $484.00K 10-K · filed 2023-02-23 |
| 2020-12-31 | $27.00K 10-K · filed 2022-03-15 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |